All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Thromboembolic events, including arterial and venous thromboembolic complications, are more common in patients with essential thrombocythemia (ET) and polycythemia vera (PV) than in the general population, and are associated with increased mortality and morbidity risks.1
Enblom-Larsson et al.1 performed a retrospective study investigating frequencies of thromboembolic and mortality events in a cohort of patients from the Swedish MPN register with ET or PV vs matched controls (MCs).
Figure 1. Rate of thromboembolic and mortality events in patients with A ET and B PV vs respective matched controls*
A
B
ET, essential thrombocythemia; PV, polycythemia vera, VTE, venous thromboembolism.
*Adapted from Enblom-Larsson A, et al.1
Key learnings |
---|
|
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox